Skip to search boxSkip to navigationSkip to main content

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

  • Ana Oaknin(corresponding author)
    ,
  • Bhavana Pothuri
    ,
  • Lucy Gilbert
    ,
  • Renaud Sabatier
    ,
  • Jubilee Brown
    ,
*Corresponding author for this work
  • Vall d'Hebron Institute of Oncology
    ,
  • New York University
    ,
  • McGill University
    ,
  • Aix-Marseille Université
    ,
  • Carolinas Healthcare System Reproductive Medicine and Infertility
    ,
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Purpose: This interim report of the GARNET phase I trial presents efficacy and safety of dostarlimab in patients with advanced or recurrent endometrial cancer (EC), with an analysis of tumor biomarkers as prognostic indicators. Patients and Methods: A total of 153 patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) and 161 patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) EC were enrolled and dosed. Patients received 500 mg dostarlimab every 3 weeks for four cycles, then 1,000 mg every 6 weeks until progression. Primary endpoints were objective response rate (ORR) and duration of response (DOR). Results: A total of 143 patients with dMMR/MSI-H EC and 156 patients with MMRp/MSS EC were evaluated for efficacy. ORR was 45.5% (n ¼ 65) and 15.4% (n ¼ 24) for dMMR/MSI-H EC and MMRp/MSS EC, respectively. Median DOR for dMMR/MSI-H EC was not met (median follow-up, 27.6 months); median DOR for MMRp/MSS EC was 19.4 months. The ORRs by combined positive score (CPS) ≥1 status were 54.9% and 21.7% for dMMR/MSI-H EC and MMRp/MSS EC, respectively. ORRs by high tumor mutational burden (≥10 mutations/Mb) were 47.8% (43/90) and 45.5% (5/11) for dMMR/MSI-H EC and MMRp/MSS EC, respectively. ORR in TP53mut or POLemut molecular subgroups was 18.1% (17/94) and 40.0% (2/5), respectively. The safety profile of dostarlimab was consistent with previous reports. Conclusions: Dostarlimab demonstrated durable antitumor activity and safety in patients with dMMR/MSI-H EC. Biomarkers associated with EC may identify patients likely to respond to dostarlimab.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 4564-4574 (11 pages)

Journal (Volume, Issue Number)

Clinical Cancer Research (Volume 29, Issue 22)

Publication milestones

  • Published - 2023

Publication status

Published - 2023

ISSN

1078-0432

Publication IDs

  • Scopus: 85174301764
  • PubMed: 37363992

Publication metrics

Metrics

Fractional count
1
Fractional count
0.05
Fractional count
20
Fractional count
0.95
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
88
Captures
36
Mentions
3

Funding Details

The GARNET trial (NCT02715284) was originally designed and funded by Tesaro Inc. (acquired by GSK in 2018) in collaboration with the authors. The authors
FundersFunding numbers
TESARO Inc.
-
GSK
-